at least one of the FOBs with sandoz was dropped because of poor commercial prospects, so i think it's safe to say at least one of the candidates was not an TNFalpha inhibitor
it would be interesting if BIIB hooked up with MNTA in FOBs - doug williams is at BIIB now and he was instrumental in enbrel's development while at immunex - he could then see the drug come full circle as a generic at BIIB :)
News 
Market Data 
Discover 
AI
